0.26% 0.0194

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short Interest - MarketBeat

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - AOL

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - Yahoo Finance

AVIR’s price-to-cash ratio: Is it a good investment at the moment? - US Post News

Atea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial Result - MarketWatch

Atea stock falls after setback to COVID-19 drug (NASDAQ:AVIR) - Seeking Alpha

Atea Pharmaceuticals reports Phase 3 trial miss for COVID-19 drug - Investing.com

Atea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary Endpoint - MarketWatch

Atea Pharmaceuticals Provides Update on Global Phase 3 - GlobeNewswire

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - StockTitan

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Acadian Asset Management LLC - Defense World

Atea stock drops as COVID-19 therapy fails in late-stage trial - MSN

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - MSN

Atea Pharmaceuticals advances antiviral drug study - Investing.com

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by SG Americas Securities LLC - Defense World

Atea Pharmaceuticals advances antiviral drug study - Investing.com India

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - ForexTV.com

Atea Pharmaceuticals Announces Publication of Additional - GlobeNewswire

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - StockTitan

California State Teachers Retirement System Cuts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Price T Rowe Associates Inc. MD Has $272,000 Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN

Atea rises after Morgan Stanley upgrade - MSN

Atea stck rises after Morgan Stanley upgrade (NASDAQ:AVIR) - Seeking Alpha

Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded to "Equal Weight" at Morgan Stanley - MarketBeat

Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded by Morgan Stanley to Equal Weight - Defense World

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy - MSN

Q3 2024 Earnings Estimate for Atea Pharmaceuticals, Inc. Issued By William Blair (NASDAQ:AVIR) - MarketBeat

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy - Yahoo Finance

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Holdings Increased by Vanguard Group Inc. - Defense World

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call Transcript - Insider Monkey

21,472 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Acquired by Tidal Investments LLC - Defense World

William Blair Weighs in on Atea Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:AVIR) - Defense World

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript - Seeking Alpha

Atea Pharmaceuticals (NASDAQ:AVIR) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS - Defense World

Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.28 EPS - MarketBeat

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Public Employees Retirement System of Ohio Has $247,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance

Atea Pharmaceuticals (AVIR) Set to Announce Earnings on Wednesday - Defense World

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - Defense World

Atea Pharmaceuticals (AVIR) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - MarketBeat

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - GlobeNewswire

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - StockTitan

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - Yahoo Finance

SG Americas Securities LLC Sells 14,381 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Examining the Potential Price Growth of Atea Pharmaceuticals Inc (AVIR) - Knox Daily

Mirae Asset Global Investments Co. Ltd. Buys New Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 5.2% in June - American Banking and Market News

Atea Pharmaceuticals Inc (AVIR) may enjoy gains as insiders got busy in the recent days - Knox Daily

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 3.2% - MarketBeat

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 3.2% - Defense World

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 3.2% - American Banking and Market News

JP Morgan downgrades Atea Pharmaceuticals Inc (AVIR) rating to an Underweight - Knox Daily

Get in on Atea Pharmaceuticals Inc's (AVIR) buy-in window today! – Sete News - SETE News

Checking in on Atea Pharmaceuticals Inc (AVIR) after recent insiders movement – Knox Daily - Knox Daily

What is Atea Pharmaceuticals Inc (AVIR) Stock Return on Shareholders' Capital? – Sete News - SETE News

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Director Sells $61228.56 in Stock - Defense World

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Director Sells $61,228.56 in Stock - MarketBeat

ADC Therapeutics (NYSE:ADCT) vs. Atea Pharmaceuticals (NASDAQ:AVIR) Financial Contrast - Defense World

After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR) - Yahoo Sport Australia

Atea Pharmaceuticals holds annual stockholder meeting, elects directors - Investing.com South Africa

Atea Pharmaceuticals holds annual stockholder meeting, elects directors - Investing.com

Atea Pharmaceuticals director sells over $61k in company stock - Investing.com South Africa

AVIR과 유사한 종목